- Previous Close
53.80 - Open
53.00 - Bid 51.95 x --
- Ask 52.05 x --
- Day's Range
51.60 - 53.00 - 52 Week Range
51.60 - 91.65 - Volume
97,843 - Avg. Volume
179,049 - Market Cap (intraday)
3.902B - Beta (5Y Monthly) 0.76
- PE Ratio (TTM)
32.53 - EPS (TTM)
1.60 - Earnings Date Feb 27, 2025
- Forward Dividend & Yield 0.85 (1.58%)
- Ex-Dividend Date May 5, 2025
- 1y Target Est
74.00
Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). The company also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. Bachem Holding AG was incorporated in 1971 and is headquartered in Bubendorf, Switzerland.
www.bachem.comRecent News: BANB.SW
View MorePerformance Overview: BANB.SW
Trailing total returns as of 3/31/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BANB.SW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BANB.SW
View MoreValuation Measures
Market Cap
4.03B
Enterprise Value
3.94B
Trailing P/E
33.62
Forward P/E
32.57
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.66
Price/Book (mrq)
2.90
Enterprise Value/Revenue
6.51
Enterprise Value/EBITDA
22.06
Financial Highlights
Profitability and Income Statement
Profit Margin
19.87%
Return on Assets (ttm)
4.61%
Return on Equity (ttm)
8.87%
Revenue (ttm)
605.26M
Net Income Avi to Common (ttm)
120.25M
Diluted EPS (ttm)
1.60
Balance Sheet and Cash Flow
Total Cash (mrq)
95.2M
Total Debt/Equity (mrq)
0.02%
Levered Free Cash Flow (ttm)
-225M